PL418671A1 - Przeciwciała monoklonalne przeciwko hemaglutyninie wirusów grypy serotypu H5 i ich zastosowania, hybrydomy produkujące rzeczone przeciwciała, kompozycje i zestawy diagnostyczne - Google Patents

Przeciwciała monoklonalne przeciwko hemaglutyninie wirusów grypy serotypu H5 i ich zastosowania, hybrydomy produkujące rzeczone przeciwciała, kompozycje i zestawy diagnostyczne

Info

Publication number
PL418671A1
PL418671A1 PL418671A PL41867116A PL418671A1 PL 418671 A1 PL418671 A1 PL 418671A1 PL 418671 A PL418671 A PL 418671A PL 41867116 A PL41867116 A PL 41867116A PL 418671 A1 PL418671 A1 PL 418671A1
Authority
PL
Poland
Prior art keywords
serotype
antibodies
compositions
hybridomas producing
monoclonal antibodies
Prior art date
Application number
PL418671A
Other languages
English (en)
Other versions
PL238020B1 (pl
Inventor
Violetta Sączyńska
Violetta Cecuda-Adamczewska
Anna Porębska
Katarzyna Florys
Anna Bierczyńska-Krzysik
Piotr Baran
Agnieszka Romanik-Chruścielewska
Grażyna Płucienniczak
Andrzej Płucienniczak
Piotr Borowicz
Krzysztof Kucharczyk
Bogusław Szewczyk
Original Assignee
Instytut Biotechnologii i Antybiotyków
Kucharczyk Krzysztof Techniki Elektroforetyczne Spółka Z Ograniczoną Odpowiedzialnością
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biotechnologii i Antybiotyków, Kucharczyk Krzysztof Techniki Elektroforetyczne Spółka Z Ograniczoną Odpowiedzialnością, Uniwersytet Gdański filed Critical Instytut Biotechnologii i Antybiotyków
Priority to PL418671A priority Critical patent/PL238020B1/pl
Priority to PCT/PL2017/000084 priority patent/WO2018048317A1/en
Priority to EP17784704.3A priority patent/EP3510045B1/en
Priority to US16/332,782 priority patent/US10696737B2/en
Publication of PL418671A1 publication Critical patent/PL418671A1/pl
Publication of PL238020B1 publication Critical patent/PL238020B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Przedmiotem zgłoszenia są przeciwciała monoklonalne przeciwko hemaglutyninie wirusów grypy serotypu H5 wybrane z grupy obejmującej G-1-31-22, G-2-14-10, G-5-32-5, G-6-42-42, G-7-24-17 i G-7-27-18, mające szerokie zastosowanie w immunoprofilaktyce i immunoterapii zakażeń wywołanych przez wirus grypy, serotypu H5 u ludzi i zwierząt. Zgłoszenie obejmuje też hybrydomy produkujące przedmiotowe przeciwciała oraz kompozycje i zestawy diagnostyczne zawierające przedmiotowe przeciwciała do wykrywania i oznaczania wirusów grypy serotypu H5 oraz przeciwciał przeciwko wirusom grypy serotypu H5 w próbach biologicznych.
PL418671A 2016-09-12 2016-09-12 Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne PL238020B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL418671A PL238020B1 (pl) 2016-09-12 2016-09-12 Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne
PCT/PL2017/000084 WO2018048317A1 (en) 2016-09-12 2017-09-11 Monoclonal antibodies against hemagglutinin of h5-serotype influenza viruses and their uses, hybridomas producing said antibodies, compositions and diagnostic kits
EP17784704.3A EP3510045B1 (en) 2016-09-12 2017-09-11 Monoclonal antibodies against hemagglutinin of h5-serotype influenza viruses and their uses, hybridomas producing said antibodies, compositions and diagnostic kits
US16/332,782 US10696737B2 (en) 2016-09-12 2017-09-11 Monoclonal antibodies against hemagglutinin of h5-serotype influenza viruses and their uses, hybridomas producing said antibodies, compositions and diagnostic kits

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL418671A PL238020B1 (pl) 2016-09-12 2016-09-12 Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne

Publications (2)

Publication Number Publication Date
PL418671A1 true PL418671A1 (pl) 2018-03-26
PL238020B1 PL238020B1 (pl) 2021-06-28

Family

ID=60117726

Family Applications (1)

Application Number Title Priority Date Filing Date
PL418671A PL238020B1 (pl) 2016-09-12 2016-09-12 Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne

Country Status (4)

Country Link
US (1) US10696737B2 (pl)
EP (1) EP3510045B1 (pl)
PL (1) PL238020B1 (pl)
WO (1) WO2018048317A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3573650A4 (en) * 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA
CN111117970B (zh) * 2020-01-20 2020-11-17 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种识别n6亚型禽流感病毒神经氨酸酶蛋白的单克隆抗体及其应用
KR102517114B1 (ko) * 2020-08-28 2023-04-03 원광대학교산학협력단 고병원성 조류 인플루엔자 바이러스 h5 아형에 특이적인 단클론항체 및 이를 이용한 신속 진단 키트
CN112175072B (zh) * 2020-09-23 2022-06-28 浙江大学医学院附属第一医院 抗h5亚型禽流感病毒血凝素蛋白单克隆抗体zju5-01及其应用
KR102605065B1 (ko) * 2021-10-14 2023-11-22 원광대학교산학협력단 고병원성 조류 인플루엔자 바이러스 h5n1에 특이적인 단클론항체 및 이를 이용한 신속 진단 키트

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110937A2 (en) 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
AU2008297594B2 (en) * 2007-09-13 2013-06-20 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
WO2012054745A1 (en) 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
WO2013105896A1 (en) 2012-01-12 2013-07-18 Temasek Life Sciences Laboratory Limited Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3

Also Published As

Publication number Publication date
WO2018048317A1 (en) 2018-03-15
US10696737B2 (en) 2020-06-30
EP3510045B1 (en) 2021-11-03
EP3510045A1 (en) 2019-07-17
WO2018048317A8 (en) 2018-05-03
US20190352375A1 (en) 2019-11-21
PL238020B1 (pl) 2021-06-28

Similar Documents

Publication Publication Date Title
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
CO2020013392A2 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2018002797A1 (es) Receptores quiméricos y métodos de uso de los mismos.
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
MX420844B (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
PL418671A1 (pl) Przeciwciała monoklonalne przeciwko hemaglutyninie wirusów grypy serotypu H5 i ich zastosowania, hybrydomy produkujące rzeczone przeciwciała, kompozycje i zestawy diagnostyczne
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
JO3555B1 (ar) جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
MA39803A (fr) Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation
UA120981C2 (uk) Антитіло, що зв'язується з il-8, та його застосування
BR112020009759A8 (pt) Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
EA201991876A1 (ru) Антитела против фактора d и их применения
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
EA201992027A1 (ru) Водный состав антитела против pd-l1
JOP20210011A1 (ar) مستقبلات خيمرية لـ steap1 وطرق استخدامها
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
WO2015143194A3 (en) Immunogenetic restriction on elicitation of antibodies
EP3339439A4 (en) MONOCLONAL ANTIBODY TO NEUTRALIZE THE INFECTIOUSITY OF ALL EBOLA VIRUSES
CL2018003871A1 (es) Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu
CL2014003373A1 (es) Anticuerpos monoclonales especificos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares , útiles para la deteccion y el diagnostico de la infeccion causada por hmpv.